1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,835 | 0,870 | 09:11 | |
| 0,835 | 0,870 | 08:22 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 389 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 02.02. | NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres | 392 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 20.01. | DealFlow Events: NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference | 841 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 13.01. | NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 | 667 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 01.12.25 | NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles | 628 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 26.11.25 | NANOVIRICIDES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.11.25 | NanoViricides GAAP EPS of -$0.10 | 16 | Seeking Alpha | ||
| 17.11.25 | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 393 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| 14.11.25 | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 600 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11.25 | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 659 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| 11.11.25 | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 646 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11.25 | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 655 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11.25 | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 619 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11.25 | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 533 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10.25 | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 670 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10.25 | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 686 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10.25 | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 588 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 20.10.25 | A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus | 614 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 15.10.25 | NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses | 574 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 23,950 | 0,00 % | Formycon vergibt FYB206-Vermarktungsrechte in Asien | Die Formycon AG hat mit Lotus Pharmaceutical eine exklusive Lizenzvereinbarung für den Keytruda-Biosimilar-Kandidaten FYB206 in weiten Teilen der Asien-Pazifik-Region geschlossen. Wie das Unternehmen... ► Artikel lesen | |
| ONTO INNOVATION | 187,00 | -0,53 % | Beyond The Numbers: 8 Analysts Discuss Onto Innovation Stock | ||
| VEECO INSTRUMENTS | 27,400 | -0,72 % | Axcelis Technologies, Inc.: Axcelis Stockholders Approve Merger with Veeco | BEVERLY, Mass., Feb. 6, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS) ("Axcelis") today announced that its stockholders have voted to approve all... ► Artikel lesen | |
| KOPIN | 1,954 | +1,51 % | Kopin Corporation: Michael Murray, Kopin's CEO to Present at THEON International's Capital Markets Day (CMD) on November 6, 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen | |
| GAUZY | 0,790 | -0,13 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Board Composition Requirements | TEL AVIV, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that it has received... ► Artikel lesen | |
| SOLESENCE | 1,360 | -5,56 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| NVE | 56,50 | -1,74 % | Dividendenbekanntmachungen (02.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY INC US00508Y1029 0,2 USD 0,1687 EUR ALLY FINANCIAL INC US02005N1000 0,3 USD 0,2531 EUR AMERISERV FINANCIAL INC US03074A1025 0... ► Artikel lesen | |
| RIBER | 5,060 | -0,78 % | RIBER: 2025 performance driven by production systems and the rollout of ROSIE | 2025 performance driven by production systems and the rollout of ROSIE Revenues of €40.3 million in line with guidanceOrder book at December 31, 2025: €26.9 million (+24%) Bezons (France), February... ► Artikel lesen | |
| ZENTEK | 0,530 | -2,75 % | Zentek Ltd.: Zentek Issues Shareholder Letter Outlining Strategic Reset and Focused Growth Plan | Guelph, Ontario--(Newsfile Corp. - January 29, 2026) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company") today announced that it has issued a letter to shareholders outlining a... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,452 | +9,71 % | Fendx Technologies Inc (2): Fendx Technologies issues 32,800 shares for services | ||
| OBDUCAT | 0,003 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 3,340 | -1,18 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| ADVANCE ZINCTEK | 0,510 | 0,00 % | ADVANCE ZINCTEK LIMITED: Return of Capital - ANO | ||
| LAMPETIA | 0,080 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| REGION GROUP | 1,316 | -1,07 % | Region Group 1H FY26 presentation: FFO growth and upgraded guidance on strong retail performance |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +1,80 % bei einem Aktienkurs von 0,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.